News

The agreement with give Apotex exclusive rights in Canada for the commercialization of APP13007.

LUBT010 is a ranibizumab biosimilar to Lucentis and the study achieved its primary endpoint

LUBT010 is a ranibizumab biosimilar to Lucentis that achieved its primary endpoint in this study.

The program is for candidate OCU400, a modifier gene therapy product candidate.

The company hosted a virtual KOL event focusing on applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on wet AMD, and ongoing SCS clinical programs.

Kay Durairaj, MD, FACS, a facial plastic surgeon points out that the use of hyaluronidase in the periorbital region demands a meticulous approach due to the delicate anatomy and high risk of complications.

This clinical milestone marks a new step in treating the condition with a potential long-term benefit.

According to the company, the wearable smart glasses with both vision enhancement and assistance will be introduced at the American Retina Forum National Meeting

Investigators at Shandong Normal University in China discovered that ciliary disassembly in photoreceptors is a significant event in the pathogenesis of retinal degeneration.

A list of 14 risk factors indicate dementia is not an inevitable consequence of aging

The Summit will feature 18+ course hours and an extensive resource library to support practice adoption of AT IOLs

According to the company, additional data from its Phase 2 ARCHER trial showed both vision protection in standard and low light conditions, and structural protection in regions of the eye key for visual acuity.

The service expands ophthalmological capabilities and enables providers to deliver the gift of sight to patients with complex retinal conditions in Harlem.

Stephanie Marioneaux, MD, gives insight into the inspiration and research discussed in her talk “First in Medicine: An African American perspective from 1700 to 1940" as the Patricia Bath Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

Researchers at National Taiwan University Hospital concluded that significant differences were observed in visual acuity, refractive state and myopia rate between patients with inherited retinal disease and the general population.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

A team of 14 eyecare professionals made the recent trip including faculty from the Loyola Medicine Department of Ophthalmology and faculty and residents from Cook County Health, Northwestern Medicine, Wills Eye Hospital in Philadelphia, the University of Toledo College of Medicine and Champlain Ophthalmology in Bethesda, Maryland.

M. Roy Wilson, MD, touches upon reconceptualizing the use of race in medicine as part of his Robert Copeland Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

The US gymnast has become an overnight sensation for competing with strabismus and coloboma at the 2024 Olympic Games in Paris.

Kathryn Colby, MD, PhD, described diagnosing and managing these tumors at the National Medical Association annual meeting, Ophthalmology Session in New York.

Fasika Woreta, MD, discussed the Roman-Barnes lecture and the cornea care landscape ahead of the National Medical Association meeting.

Ore-ofe O. Adesina, MD, described the advances in diagnostics and therapeutics in Neuro-Ophthalmology at the National Medical Association annual meeting.

Statin use was linked with increased glaucoma likelihood in the overall adult All of Us Research Program population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals from 60 to 69 years old.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

The nonprofit Prevent Blindness recognised the awareness month with a slate of resources

The company is developing ixoberogene soroparvovec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD.

According to the researchers, the findings suggest drusen formation is a downstream effect of AKT2-related lysosome dysfunction and points to a new target for therapeutic intervention.